The 5-yr survival rate for the adenocarcinoma patients was 19 vs. 7% in the remainder of patients. Of 39 patients referred for surgery, 37 had lung resections and their 5-yr survival rate was 42%. Post-operative staging showed 48% in Stage Ⅰ, 27% in Stage Ⅱ and 24% in Stage Ⅲ...
The 5-yr survival rate for the adenocarcinoma patients was 19 vs. 7% in the remainder of patients. Of 39 patients referred for surgery, 37 had lung resections and their 5-yr survival rate was 42%. Post-operative staging showed 48% in Stage Ⅰ, 27% in Stage Ⅱ and 24% in Stage Ⅲ...
Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epiderm... V Hirsh,K Park,EH Tan,... - 《European Journal of...
STAS probably contributes to the high recurrence rate for patients with small stage I adenocarcinomas who undergo limited surgical resections and the poor prognosis observed by others.12,33 Solid Predominant Invasive Adenocarcinoma The solid subtype with mucin production consists of a major component of...
Lung cancer is the second most common cancer in Taiwan. After Taiwan implemented the Tobacco Hazards Prevention Act in 1997, smoking rates declined. However, the incidence rates of lung cancer for both sexes are still increasing, possibly due to risk fac
Ubiquitin specific protease 4 (USP4) is a member of the USPs family, which catalyzes the cleavage of ubiquitin from a series of protein substrates, thereby modulating a number of cellular signaling pathways. In this study, we aimed to explore the expression profile of USP4 in lung adenocarcinoma...
Finally, we investigated the clinical significance of the miR-16 family/TFAP2A/ PSG9 axis. First, we assessed the impact of the TFAP2A/PSG9 combination on survival rate by comparing patients of three groups divided by gene expression level (TFAP2A+PSG9+, TFAP2A-PSG9-, and Other) in ...
Overall survival was calculated from the date of surgery until either death from any cause or date of last follow-up, with a minimum of 1.5 years of study inclusion. Variables considered included ethnicity, stage and size of the DT, genetic mutations, smoking status, and number and size of ...
Most of the previous prognostic models of lung adenocarcinoma focused on the clinical factors, such as treatment, tumour node metastasis (TNM) stage, and tumour grade4,5. These models may not be able to accurately predict the survival of patients with lung adenocarcinoma. With the development of...
The complexity of the tumor microenvironment (TME) is a crucial factor in lung adenocarcinoma (LUAD) progression. To gain deeper insights into molecular mechanisms of LUAD, we perform an integrative single-cell RNA sequencing (scRNA-seq) data analysis of